GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Debt-to-Revenue

ATAI Life Sciences NV (FRA:9VC) Debt-to-Revenue : 17.95 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

ATAI Life Sciences NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.22 Mil. ATAI Life Sciences NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €18.02 Mil. ATAI Life Sciences NV's annualized Revenue for the quarter that ended in Jun. 2024 was €1.02 Mil. ATAI Life Sciences NV's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 17.95.


ATAI Life Sciences NV Debt-to-Revenue Historical Data

The historical data trend for ATAI Life Sciences NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Debt-to-Revenue Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A 0.04 65.83 60.95

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.24 47.62 258.13 N/A 17.95

Competitive Comparison of ATAI Life Sciences NV's Debt-to-Revenue

For the Biotechnology subindustry, ATAI Life Sciences NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Debt-to-Revenue falls into.



ATAI Life Sciences NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

ATAI Life Sciences NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.252 + 17.301) / 0.288
=60.95

ATAI Life Sciences NV's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.222 + 18.016) / 1.016
=17.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.


ATAI Life Sciences NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV Business Description

Traded in Other Exchanges
Address
Wallstrasse 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV Headlines

No Headlines